Ana Pena, PhD,  —

Early accumulation of abnormally thick mucus and inflammation in the lungs, rather than bacterial infections, may be the initial trigger of lung disease during cystic fibrosis (CF), a new study suggests. Bacterial infections have been thought of as an early driver…

Resura Prenatal Test, the first non-invasive prenatal test for single-gene (monogenic) disorders such as cystic fibrosis (CF), has been launched by  biotech company Progenity. The test screens fetal cell-free DNA from a sample of maternal blood. According to the company, this test is the first…

Eloxx Pharmaceuticals presented new positive preclinical data for ELX-02, its lead treatment candidate for cystic fibrosis (CF), demonstrating that the therapy increases the levels of CFTR protein and its correct placement at the cell’s surface in patient-derived organoids. Findings were presented by Shira Landskroner-Eiger, PhD, Eloxx’s principal…

Xolair (omalizumab), a medicine used for allergic asthma and chronic hives, is effective for treating lung allergic reactions caused by fungi in patients with cystic fibrosis (CF), a case report suggests. The study reports three cases of allergic bronchopulmonary…

A new method to estimate the best dose of enzyme supplements for pancreatic enzyme replacement therapy (PERT) based on different meals shows promise in young patients with cystic fibrosis (CF), according to a pilot study. According to…

Amphotericin B, a widely used antifungal medication, may be a potential treatment to restore lung mucus properties, including its ability to fight infections, in people with cystic fibrosis (CF), a preliminary study shows. The medicine creates pores in the membrane of cells lining the airways, working as a…

Joint disease, or arthropathy, is common among people with cystic fibrosis (CF), and more likely to occur in older and female patients, and those who have more pulmonary flares or elevated blood levels of IgG antibodies, a study suggests. The higher number of flares and increased…

An inhaled form of messenger RNA (mRNA) with the potential to safely deliver therapeutics to the lungs of cystic fibrosis (CF) patients has been discovered by researchers at the Massachusetts Institute of Technology (MIT). Researchers developed a type of nanoparticle given as an inhaled mist (nebulizer) that allows the…

The effects of CFTR modulator therapies such as Kalydeco (ivacaftor) can be more reliably assessed using a test that specifically measures the sweating dependent on CFTR, called C-sweat rate, than using classic sweat tests or lung function measurements, a study reports. This kind of test was sensitive enough to reveal that…

Cystic fibrosis (CF) patients with liver disease do not experience greater lung function decline compared with CF patients without liver presentation, a study reports. The study, “Analysis of a large cohort of cystic fibrosis patients with severe liver disease indicates lung function…